HR 5925 RFS 
treating such disorders with medication-assisted 
treatment therapies. 
‘‘(2) CONSULTATION.—For the planning of the 
campaign under paragraph (1), the Director shall 
consult with— 
‘‘(A) the head of any appropriate National 
Drug Control Program Agency to obtain advice 
on evidence-based scientific information for pol-
icy, program development, and evaluation; 
‘‘(B) experts in evidence-based media cam-
paigns, education, evaluation, and communica-
tion; 
‘‘(C) experts on the designated drug; 
‘‘(D) State, local, and Tribal government 
officials and relevant agencies; 
‘‘(E) the public; 
‘‘(F) appropriate congressional committees; 
and 
‘‘(G) any other affected person, as deter-
mined by the Director. 
‘‘(3) GIFTS AND DONATIONS.— 
‘‘(A) IN GENERAL.—The Director may ac-
cept gifts and donations (in cash or in kind, in-
cluding voluntary and uncompensated services 
or property), which shall be available until ex-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00073
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
pended, for the purpose of supporting the edu-
cation and public awareness campaign author-
ized in this section, including the media cam-
paign. 
‘‘(B) ETHICS GUIDELINES.—The Director 
shall establish written guidelines setting forth 
the criteria to be used in determining whether 
a gift or donation should be declined under this 
section because the acceptance of the gift or do-
nation would— 
‘‘(i) reflect unfavorably upon the abil-
ity of the Director or the Office, or any 
employee of the Office, to carry out re-
sponsibilities or official duties under this 
chapter in a fair and objective manner; or 
‘‘(ii) compromise the integrity or the 
appearance of integrity of programs or 
services provided under this chapter or of 
any official involved in those programs or 
services. 
‘‘(4) IMPLEMENTATION.— 
‘‘(A) IN GENERAL.—For any campaign es-
tablished under this subsection, the Director 
shall ensure the following: 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00074
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(i) Implementation is evidence-based, 
meets accepted standards for public aware-
ness campaigns, and uses available re-
sources in a manner to make the most 
progress toward achieving the goals identi-
fied in the Emerging Threats Response 
Plan and the requirements of paragraph 
(1). 
‘‘(ii) 
Information 
disseminated 
through the campaign is accurate. 
‘‘(iii) The Director approves the strat-
egy of the campaign, all material distrib-
uted through the campaign, and the use of 
any Federal funds used for the campaign. 
‘‘(iv) The campaign is designed using 
strategies found to be most effective at 
achieving such goals and requirements of 
paragraph (1), which may include— 
‘‘(I) a media campaign, as de-
scribed in subparagraph (B); 
‘‘(II) local, regional, or popu-
lation specific messaging; 
‘‘(III) establishing partnerships 
and promoting coordination among 
community 
stakeholders, 
including 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00075
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
public, nonprofit organizations, and 
for profit entities; 
‘‘(IV) providing support, train-
ing, and technical assistance to estab-
lish and expand school and commu-
nity prevention programs; 
‘‘(V) creating websites to pub-
licize and disseminate information; 
‘‘(VI) conducting outreach and 
providing educational resources for 
parents; 
‘‘(VII) establishing State or re-
gional advisory councils to provide 
input and recommendations to raise 
awareness regarding the drug des-
ignated as an emerging drug threat; 
‘‘(VIII) collaborating with law 
enforcement; and 
‘‘(IX) support for school-based 
public health education classes to im-
prove teen knowledge about the effects 
of such designated drug. 
‘‘(B) MEDIA
CAMPAIGN.—Any campaign 
implemented under this subsection may include 
a media component, which— 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00076
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(i) shall be designed to prevent the 
use of the drug designated as an emerging 
drug threat and to achieve the goals and 
requirements of paragraph (1); 
‘‘(ii) shall be carried out through com-
petitively awarded contracts to entities pro-
viding for the professional production and 
design of such campaign; and 
‘‘(iii) may include the use of tele-
vision, radio, Internet, social media, and 
other commercial marketing venues and 
may be targeted to specific age groups 
based on peer-reviewed social research. 
‘‘(C) REQUIRED NOTICE FOR COMMUNICA-
TION FROM THE OFFICE.—Any communication, 
including an advertisement, paid for or other-
wise disseminated by the Office directly or 
through a contract awarded by the Office shall 
include a prominent notice informing the audi-
ence that the communication was paid for by of 
the Office. 
‘‘(5) EVALUATION.— 
‘‘(A) PERFORMANCE
EVALUATION.—The 
Director shall include an evaluation of the cam-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00077
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
paign in the annual assessment under section 
1006, which shall include the following: 
‘‘(i) A performance evaluation of the 
campaign, including progress toward meet-
ing the goals, objectives, measures, and 
targets identified in the Emerging Threats 
Response Plan. 
‘‘(ii) A description of all policies and 
practices to eliminate the potential for 
waste, fraud, abuse, and to ensure Federal 
funds are used responsibly. 
‘‘(iii) A list of all contracts or other 
agreements entered into to implement the 
campaign. 
‘‘(iv) The results of any financial 
audit of the campaign. 
‘‘(v) A description of any evidence 
used to develop the campaign. 
‘‘(vi) The sources and amount of each 
gift or donation accepted by the Office, 
and the source and amount of each gift or 
donation accepted by a contractor to be 
used in its performance of a contract for 
the campaign. 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00078
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(B) INDEPENDENT
EVALUATION.—Not 
later than 180 days after establishing a cam-
paign under paragraph (1) and not less than 
frequently than every 2 years thereafter, the 
Director shall— 
‘‘(i) designate an independent entity 
to evaluate the effectiveness of the cam-
paign with meeting the goals established in 
the Emerging Threat Response Plan and 
the requirements of paragraph (1); and 
‘‘(ii) submit the results of the inde-
pendent evaluation to the appropriate con-
gressional committees. 
‘‘(6) FUNDING
PROHIBITIONS.—None of the 
amounts made available under this subsection may 
be obligated for any of the following: 
‘‘(A) To supplant current anti-drug com-
munity-based coalitions. 
‘‘(B) To supplant pro bono public service 
time donated by national and local broadcasting 
network for other public services campaigns. 
‘‘(C) For partisan political purposes, or ex-
press advocacy in support of or to defeat any 
clearly identified candidate, clearly identified 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00079
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
ballot initiative, or clearly identified legislative 
or regulatory proposal. 
‘‘(D) For any advocacy in support of any 
particular company, industry association, or ad-
vocacy group or the explicit policy positions 
held by such groups. 
‘‘(E) To direct any individuals to a specific 
type of substance use disorder treatment, treat-
ment facility, medical provider, or form of medi-
cation assisted treatment. 
‘‘(F) To fund any advertising that features 
any elected officials, persons seeking elected of-
fice, cabinet level officials, or other Federal offi-
cials employed pursuant to section 213 of 
Schedule C of title 5, Code of Federal Regula-
tions. 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to the Office to carry out 
this section, $25 million for each of fiscal years 2019 
through 2023. 
‘‘§ 1010. National and international coordination 
‘‘(a) DISSEMINATION OF RESEARCH AND INFORMA-
TION TO STATES.—The Director shall ensure that drug 
control research and information is effectively dissemi-
nated by National Drug Control Program Agencies to 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00080
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
State and local governments and nongovernmental entities 
involved in demand reduction by— 
‘‘(1) encouraging formal consultation between 
any such agency that conducts or sponsors research, 
and any such agency that disseminates information 
in developing research and information product de-
velopment agendas; 
‘‘(2) encouraging such agencies (as appropriate) 
to develop and implement dissemination plans that 
specifically target State and local governments and 
nongovernmental entities involved in demand reduc-
tion; and 
‘‘(3) supporting the substance abuse informa-
tion clearinghouse administered by the Assistant 
Secretary for Mental Health and Substance Use and 
established in section 501(d)(16) of the Public 
Health Service Act by— 
‘‘(A) encouraging all National Drug Con-
trol Program Agencies to provide all appro-
priate and relevant information; and 
‘‘(B) supporting the dissemination of infor-
mation to all interested entities. 
‘‘(b) STANDARDS.— 
‘‘(1) DEVELOPMENT.—The Director shall co-
ordinate the development of evidence-based stand-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00081
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
ards developed by National Drug Control Program 
Agencies and other relevant agencies and non-Fed-
eral entities to State, local, and Tribal governments 
and nongovernmental entities related to drug control 
policies, practices, and procedures, such as the inves-
tigation of drug-related deaths, by— 
‘‘(A) encouraging appropriate agencies and 
State, local, and Tribal governments to develop 
data standards for drug control practices and 
procedures and related statistical data; 
‘‘(B) encouraging information sharing be-
tween appropriate agencies and State, local, 
and Tribal governments of relevant drug control 
information and data; 
‘‘(C) establishing a working group of agen-
cies, State, local, and Tribal governments, and 
other relevant stakeholders to discuss and de-
velop such standards; and 
‘‘(D) facilitating collaboration among agen-
cies, non-Federal entities, States, local, and 
Tribal 
governments, 
and 
nongovernmental 
agencies. 
‘‘(2) IMPLEMENTATION.—The Director shall 
promote the implementation of the standards de-
scribed in paragraph (1) by— 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00082
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
‘‘(A) encouraging adoption by providing 
the standards to State and local governments 
through the internet, annual publications or 
periodicals, 
and 
other 
widely-disseminated 
means; and 
‘‘(B) facilitating the use and dissemination 
of such standards among State and local gov-
ernments by— 
‘‘(i) providing technical assistance to 
State, local, and Tribal governments seek-
ing to adopt or implement such standards; 
and 
‘‘(ii) coordinating seminars and train-
ing sessions for State, local, and Tribal 
governments seeking to adopt or imple-
ment such standards. 
‘‘(c) PRIVATE SECTOR.— 
‘‘(1) IN GENERAL.—The Director or the head 
of a National Drug Control Program (as designated 
by the Director) shall coordinate with the private 
sector to promote private research and development 
of medications to treat or prevent addiction, includ-
ing research and development for non-addictive pain 
management medication, abuse deterrent formula-
tions, medication-assisted treatment, and other ad-
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00083
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS
HR 5925 RFS 
diction research determined to be necessary by the 
Director by— 
‘‘(A) encouraging the sharing of informa-
tion regarding evidence-based treatment addic-
tion findings and related data between agencies 
and the private sector, as appropriate; 
‘‘(B) encouraging collaboration between 
appropriate agencies and the private sector; and 
‘‘(C) providing private sector entities with 
relevant statistical data and information to en-
hance research as permissible. 
‘‘(2) WORKING GROUP.—The Director may es-
tablish a working group of National Drug Control 
Program Agencies, State, local, and Tribal govern-
ments, and the private sector stakeholders to discuss 
and disseminate best practices, research and devel-
opment, and other related issues, as appropriate. 
‘‘(d) MODEL ACTS PROGRAM.— 
‘‘(1) IN GENERAL.—The Director shall provide 
for or shall enter into an agreement with a nonprofit 
organization to— 
‘‘(A) advise States on establishing laws 
and policies to address illicit drug use issues; 
and 
VerDate Sep 11 2014 
23:16 Jun 21, 2018
Jkt 079200
PO 00000
Frm 00084
Fmt 6652
Sfmt 6201
E:\BILLS\H5925.RFS
H5925
sradovich on DSK3GMQ082PROD with BILLS